Venture Fund Iii, L.P.River... Net Worth

The estimated Net Worth of Venture Fund Iii, L.P.River... is at least $103 Milión dollars as of 12 May 2020. Venture River owns over 1,150,000 units of Allakos Inc stock worth over $3,507,809 and over the last 6 years Venture sold ALLK stock worth over $99,515,452.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Venture River ALLK stock SEC Form 4 insiders trading

Venture has made over 8 trades of the Allakos Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Venture sold 1,150,000 units of ALLK stock worth $81,696,000 on 12 May 2020.

The largest trade Venture's ever made was selling 1,150,000 units of Allakos Inc stock on 12 May 2020 worth over $81,696,000. On average, Venture trades about 192,429 units every 73 days since 2018. As of 12 May 2020 Venture still owns at least 5,750,506 units of Allakos Inc stock.

You can see the complete history of Venture River stock trades at the bottom of the page.

What's Venture River's mailing address?

Venture's mailing address filed with the SEC is 900 S Hanley Rd, St. Louis, MO 63105, USA.

Insiders trading at Allakos Inc

Over the last 6 years, insiders at Allakos Inc have traded over $246,100,922 worth of Allakos Inc stock and bought 5,181,222 units worth $35,384,176 . The most active insiders traders include Paul Edward Walker, Group, Llc Green Jeremy Red... a Daniel Janney. On average, Allakos Inc executives and independent directors trade stock every 43 days with the average trade being worth of $114,372. The most recent stock trade was executed by Harlan Baird Radford on 28 June 2024, trading 87,064 units of ALLK stock currently worth $87,935.

What does Allakos Inc do?

allakos inc is a biotechnology company located in 7400 paseo padre pkwy, fremont, ca, united states.

Complete history of Venture River stock trades at Allakos Inc

Allakos Inc executives and stock owners

Allakos Inc executives and other stock owners filed with the SEC include:

• Robert Alexander,
  Chief Executive Officer, Director
• Adam Tomasi,
  President, Chief Operating Officer
• Henrik Rasmussen,
  Chief Medical Officer
• Leo Redmond,
  Chief Financial Officer
• Mark Asbury,
  Chief Legal Officer and General Counsel
• Dr. Robert Alexander Ph.D.,
  CEO & Director
• Dr. Adam L. Tomasi Ph.D.,
  Pres & COO
• Dr. Henrik Sandvad Rasmussen,
  Strategic Advisor
• Mark Asbury,
  Chief Legal Officer & Gen. Counsel
• Daniel Janney,
  Independent Chair of the Board
• Robert Andreatta,
  Independent Director
• John McKearn,
  Independent Director
• Paul Walker,
  Independent Director
• Steven James,
  Independent Director
• Dr. Craig Paterson M.D.,
  Chief Medical Officer
• Alan Chang,
  Director of Medical Affairs & Data Analytics
• Tim Varacek,
  Chief Commercial Officer
• Dr. Sally D. Bolmer,
  Sr. VP of Regulatory Affairs & Drug Devel.
• Dr. Ruby Casareno Ph.D.,
  Sr. VP of Technical Operations
• Baird Radford III,
  Chief Financial Officer
• Group, Llc Green Jeremy Red...,
  
• Venture Fund Iii, L.P.River...,
  
• Partners Viii, L.P.Alta Par...,
  
• Neil Murray Hamilton Graham,
  
• Amy L Ladd,
  
• Dolca Thomas,
  
• Partners Next Gen Fund I Ma...,
  
• Peter A Hudson,
  
• Robert J More,
  
• Guy P Nohra,
  10% owner
• Natalie C. Holles,
  Director
• Partners Next Gen Fund I Ma...,
  
• Margaret Nell Fitzgerald,
  General Counsel and Secretary
• Craig A. Paterson,
  Chief Medical Officer
• Everett Rand Sutherland,
  Director
• Partners Management Viii, L...,
  
• Chin Hyok Lee,
  Chief Medical Officer
• Harlan Baird Radford,
  Chief Financial Officer